Supervivencia en pacientes con cáncer de mama estadio IV inicial con manejo sistémico y quirúrgico

Bravo, F., Vásquez Trespalacios, E. M., Oviedo, A., Herazo, F., & Cuello, J. (2024). Survival in patients with stage IV breast cancer with systemic and surgical management. Oncology Journal (Ecuador), 34(1), 21–35. https://doi.org/10.33821/737

Abstract

Introduction: Systemic therapy is the standard treatment in patients with metastatic breast cancer at debut. However, combined therapy (systemic therapy plus local/locoregional surgery) is under investigation to determine if it offers additional benefit on oncologic outcomes. Randomized clinical trials (RCTs) have yielded contradictory reports regarding overall survival (OS), while retrospective studies show a favorable impact. This investigation aims to describe the OS and progression-free survival (PFS) of patients with metastatic breast cancer at debut, treated with systemic therapy only or combined therapy. Materials and method: A retrospective cohort study of patients with metastatic breast cancer at the debut treated in a specialized cancer care center in Colombia. Two groups were evaluated: EST vs CT, i.e., systemic therapy and breast surgery, respectively. The primary outcomes were PFS and OS, calculated using Kaplan-Meier survival functions and adjusted for confounding variables with Cox models. Results: 174 patients received EST, and 88 patients received CT. Median follow-up was 58.38 months; PFS was 38.56 months in the EST group vs 72.25 months in the CT group. OS was 42.4 months (95% CI 33.23-51.56) in the EST group vs. 82.33 (95% CI 62.1-102.55) in the CT group; both results were statistically significant for the surgical group. Conclusion: In patients with metastatic breast carcinoma at debut, OS and PFS were better in those treated with CT than in those managed with EST.

https://doi.org/10.33821/737

Descargar el PDF (Español (España))

Download the PDF

HTML

XML

References

Badwe R, Hawaldar R, Nair N, Kaushik R, Parmar V, Siddique S, et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: An open-label randomised controlled trial. Lancet Oncol. 2015;16(13): 1380-8. https://doi.org/10.1016/S1470-2045(15)00135-7

Sabel M, Truong P, The role of local therapies in metastatic breast cancer, UpToDate, 2022, Inc.

Gradishar W, Anderson B, Abraham J, Aft R, Agnese D, Allison K, et al. Breast cancer version 4.2023. J Natl Compr Canc Netw. 2023;21(6): 594-608. https://doi.org/10.6004/jnccn.2023.0031.

Gera R, Chehade H, Wazir U, Tayeh S, Kasem A, Mokbel K. Locoregional therapy of the primary tumour in de novo stage IV breast cancer in 216 066 patients: A meta-analysis. Sci. Rep. 2020;10(1): 1-11. https://doi.org/10.1038/s41598-020-59908-1

Fitzal F, Bjelic-Radisic V, Knauer M, Steger G, Hubalek M, Balic M, et al. Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial. Ann Surg. 2019;269(6): 1163-69. https://doi.org/10.1097/SLA.0000000000002771

Soran A, Ozmen V, Ozbas S, Karanlik H, Muslumanoglu M, Igci, A, et al. Randomized trial comparing resection of primary tumor with no surgery in stage IV breast cancer at presentation: Protocol MF07-01. Ann. Surg. Oncol. 2018;25(11): 3141-149. https://doi.org/10.1245/s10434-018-6494-6

Khan SA, Zhao F, Goldstein LJ, Cella D, Basik M, Golshan M, et al. Early local therapy for the primary site in de novo stage IV breast cancer: Results of a randomized clinical trial (E2108). J Clin Oncol. 2022;40(9): 978-87. https://doi.org/10.1200/JCO.21.02006

Huang Z, Tan Q, Qin Q, Mo Q, Wei C. Impact of primary site surgery on survival of patients with de novo stage IV breast cancer. Cancer Manag Res. 2021;13: 319-27. https://doi.org/10.2147/CMAR.S280470

Babiera GV, Rao R, Feng L, Meric-Bernstam F, Kuerer HM, Singletary SE, et al. Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol. 2006;13(6):776-82. https://doi.org/10.1245/ASO.2006.03.033

Rapiti E, Verkooijen HM, Vlastos G, Fioretta G, Neyroud-Caspar I, Sappino AP, et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol. 2006;24(18):2743-9. https://doi.org/10.1200/JCO.2005.04.2226

Kim KN, Qureshi MM, Huang D, Ko NY, Cassidy M, Oshry L, et al. The impact of locoregional treatment on survival in patients with metastatic breast cancer: A National Cancer Database Analysis. Clin Breast Cancer. 2020;20(2): e200-13. https://doi.org/10.1016/j.clbc.2019.12.010

Pons-Tostivint E, Kirova, Y, Lusque A. Campone M, Geffrelot J, Mazouni C, et al. Survival impact of locoregional treatment of the primary tumor in de novo metastatic breast cancers in a large multicentric cohort study: A Propensity Score-Matched Analysis. Ann Surg Oncol. 2019;26: 356-65. https://doi.org/10.1245/s10434-018-6831-9

Hortobagyi G, Conolly J, D’orsi C, Edge S, Mittendorf E, Rugo H, et al. Abreast. En: Amin M, Edge S, Greene F, Byrd D, Brookland R, Kay M. (Eds), AJCC Cancer Staging Manual, American College of Surgeon, 8th ed. Chicago: Springer; 2017, pp. 589-636.

Díaz S, Briceño X, Puerto LJ, Lehmann C, Orozco MC, Guzmán LH, et al Factors Associated with Time to Progression and Overall Survival in Patients with De Novo Metastatic Breast Cancer: A Colombian Cohort. Oncologist. 2022 Mar 4;27(2): e142-50. https://doi.org/10.1093/oncolo/oyab023

Khan SA, Stewart AK, Morrow M. Does aggressive local therapy improve survival in metastatic breast cancer? Surgery. 2002;132(4): 620-6. https://doi.org/10.1067/msy.2002.127544

Rapiti E, Verkooijen HM, Vlastos G, Fioretta G, Neyroud-Caspar I, Sappino AP, et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol. 2006;24(18): 2743-9. https://doi.org/10.1200/JCO.2005.04.2226

Blanchard D, Shetty P, Hilsenbeck S, Elledge R. Association of surgery with improved survival in stage IV breast cancer patients. Ann Surg. 2008;247: 732-8. https://doi.org/10.1097/SLA.0b013e3181656d32

Thomas A, Khan SA, Chrischilles EA, Schroeder MC. Initial Surgery and Survival in Stage IV Breast Cancer in the United States, 1988-2011. JAMA Surg. 2016;151(5): 424-31. https://doi.org/10.1001/jamasurg.2015.4539

Jiménez J, Sánchez B, Machuca P, Navarro J, Dueñas B. Tratamiento quirúrgico del tumor primario en pacientes con cáncer de mama en estadio IV. Cir Esp. 2015;93(6): 375-80. https://doi.org/10.1016/j.ciresp.2014.09.005

Tosello G, Torloni MR, Mota BS, Neeman T, Riera R. Breast surgery for metastatic breast cancer. Cochrane Database Syst Rev. 2018;3(3): CD011276. https://doi.org/10.1002/14651858.CD011276.pub2

Bermas HR, Khan SA. Local therapy for the intact breast primary in the presence of metastatic disease. En: Bland KI, Copeland EM (Eds). The breast, comprehensive management of benign and malignant disease, 4.a ed., vol. 2. Philadelphia: Elsevier Health Sciences; 2009, pp. 1211-21. https://doi.org/10.1016/B978-1-4160-5221-0.00074-7

Ren Z, Li Y, Hameed O, Siegal GP, Wei S. Prognostic factors in patients with metastatic breast cancer at the time of diagnosis. Pathol Res Pract. 2014;210(5): 301-6. https://doi.org/10.1016/j.prp.2014.01.008

Ranji P, Salmani Kesejini T, Saeedikhoo S, Alizadeh AM. Targeting cancer stem cell-specific markers and/or associated signaling pathways for overcoming cancer drug resistance. Tumour Biol. 2016;37(10): 13059-75. https://doi.org/10.1007/s13277-016-5294-5

Bauernhofer T, Zenahlik S, Hofmann G, Balic M, Resel M, Pirchmoser R, et al. Association of disease progression and poor overall survival with detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer. Oncol Rep. 2005;13: 179-84. https://pubmed.ncbi.nlm.nih.gov/15643496/

Bidard FC, Vincent-Salomon A, Sigal-Zafrani B, Diéras V, Mathiot C, Mignot L, et al. Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells. Ann Oncol. 2008;19: 496-500. https://doi.org/0.1093/annonc/mdm507

Rashid OM, Nagahashi M, Ramachandran S, Graham L, Yamada A, Spiegel S, et al. Resection of the primary tumor improves survival in metastatic breast cancer by reducing overall tumor burden. Surgery. 2013;153(6): 771-8. https://doi.org/10.1016/j.surg.2013.02.002

Sandri MT, Zorzino L, Cassatella MC, Bassi F, Luini A, Casadio C, et al. Changes in circulating tumor cell detection in patients with localized breast cancer before and after surgery. Ann Surg Oncol. 2010;17(6): 1539-45. https://doi.org/10.1245/s10434-010-0918-2

Andergassen U, Zebisch M, Kolbl AC, König A, Heublein S, Schröder L, et al. Real-time qPCR-based detection of circulating tumor cells from blood samples of adjuvant breast cancer patients: a preliminary study. Breast Care (Basel). 2016;11: 194-8. https://doi.org/10.1159/000447041

Schindlbeck C, Andergassen U, Jueckstock J, Rack B, Janni W, Jeschke U. Disseminated and circulating tumor cells in bone marrow and blood of breast cancer patients: properties, enrichment, and potential targets. J Cancer Res Clin Oncol. 2016;142: 1883-95. https://doi.org/10.1007/s00432-016-2118-3

Balic M, Lin H, Young L, Hawes D, Giuliano A, McNamara G, et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res. 2006;12: 5615-21. https://doi.org/10.1158/1078-0432.CCR-06-0169

Santa-Maria CA, Gradishar WJ. Changing treatment paradigms in metastatic breast cancer: lessons learned. JAMA Oncol. 2015;1(4): 528-34. https://doi.org/10.1001/jamaoncol.2015.1198

Leung AM, Vu HN, Nguyen KA, Thacker LR, Bear HD. Effects of surgical excision on survival of patients with stage IV breast cancer. J Surg Res. 2010;161(1): 83-8. https://doi.org/10.1016/j.jss.2008.12.030

Cady B, Nathan NR, Michaelson JS, Golshan M, Smith BL. Matched pair analyses of stage IV breast cancer with or without resection of primary breast site. Ann Surg Oncol. 2008;15(12):3384-95. https://doi.org/10.1245/s10434-008-0085-x